Mar 09, 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Dec 02, 2019
Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri(TM) (trastuzumab-dkst), in the U.S.
Oct 19, 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
Sep 21, 2018
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
Jun 04, 2018
U.S. FDA Approves Mylan and Biocon's Fulphila(TM) (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
Jun 01, 2018
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri(TM), the first biosimilar for Herceptin® approved by FDA
Mar 27, 2018
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee(TM), Biosimilar Insulin Glargine
Jan 29, 2018
Mylan and Biocon Receive Positive CHMP Opinion for Semglee(TM), Biosimilar Insulin Glargine
Dec 29, 2017
Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
Dec 23, 2017
Bringing Access to Biologics
Dec 01, 2017
U.S. FDA Approves Mylan and Biocon's Ogivri(TM), the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
Nov 30, 2017
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim
Oct 09, 2017
Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference
Jul 13, 2017
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
Jun 10, 2017
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions